株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Orphagen Pharmaceuticals, Inc.:製品パイプライン分析

Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 314191
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Orphagen Pharmaceuticals, Inc.:製品パイプライン分析 Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年06月30日 ページ情報: 英文 22 Pages
概要

Orphagen Pharmaceuticals, Inc.は、核内オーファン受容体を標的とする小分子薬を開発する製薬会社です。この核内受容体には、自己免疫疾患、睡眠・覚醒障害、代謝疾患、気分障害が含まれます。

当レポートでは、Orphagen Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Orphagen Pharmaceuticals, Inc.の基本情報

Orphagen Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

Orphagen Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

Orphagen Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Orphagen Pharmaceuticals, Inc.:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Orphagen Pharmaceuticals, Inc.:薬剤プロファイル

  • OR-1050
  • Steroidogenic Factor-1を遮断する小分子
  • 核内受容体を調節する概日リズム睡眠障害向け小分子
  • 核内受容体を調節するAMD向け小分子
  • 核内受容体を調節するGBM向け小分子
  • 核内受容体を調節する網膜色素変性向け小分子

Orphagen Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Orphagen Pharmaceuticals, Inc.:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07219CDB

Summary

Global Markets Direct's, 'Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Orphagen Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orphagen Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Orphagen Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Orphagen Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Orphagen Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Orphagen Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Orphagen Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Orphagen Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Orphagen Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orphagen Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Orphagen Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Orphagen Pharmaceuticals, Inc. Snapshot
    • Orphagen Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Orphagen Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Orphagen Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products Glance
    • Orphagen Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Orphagen Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Orphagen Pharmaceuticals, Inc. - Drug Profiles
    • OR-1050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for AMD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Glioblastoma Multiforme
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Retinitis Pigmentosa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Orphagen Pharmaceuticals, Inc. - Pipeline Analysis
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Target
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Orphagen Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Orphagen Pharmaceuticals, Inc., Key Information
  • Orphagen Pharmaceuticals, Inc., Key Facts
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Orphagen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Orphagen Pharmaceuticals, Inc. - Phase I, 2015
  • Orphagen Pharmaceuticals, Inc. - Discovery, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Orphagen Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Orphagen Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top